Presence of Fc Receptors for IgA on Rat Alveolar Macrophages but not Peritoneal Macrophages

  • Y. Sibille
  • B. Chatelain
  • Ph. Staquet
  • M. Rits
  • J.-P. Vaerman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 216 A)


Different blood cells, including lymphocytes, polymorphonuclear leukocytes and monocytes, possess a receptor for the Fc portion of IgA (FcaR) on their surface (1–4). Recently, an FcaR has also been demonstrated on mouse alveolar marcrophages (AM) but not peritoneal macrophages (PM) (5), and the IgA-mediated phagocytosis correlated with the presence of FcaR (6). Despite early studies reporting the absence of FcaR on rat and human AM (7,8), up to 17% of human AM can ingest sIgA-opsonized Pseudomonas (9). Further, a possible role of AM has been suggested in a rat model of IgA-induced lung injury (10). Therefore, the present study was designed to assess by flow cytometry the issue of FcaR on rat AM and PM and to investigate whether the molecular size of IgA could influence its binding to the cells.


Peritoneal Macrophage Peritoneal Lavage Peritoneal Lavage Fluid Bovine Serum Albumin Control Alveolar Line Fluid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lum, L.G., Muchmore, A.V., Keren, D., Decker, J., Koshi, I., Strober, W. and Blaese, R.M., J. Immunol. 122, 65, 1979.PubMedGoogle Scholar
  2. 2.
    Lum, L.G., Muchmore, A.V., O’Connor, W., Strober, W. and Blaese, R.M., J. Immunol. 123, 714, 1979.PubMedGoogle Scholar
  3. 3.
    Fanger, M.W., Pugh, J. and Bernier, G.M., Cell. Immunol. 60, 324, 1981.PubMedCrossRefGoogle Scholar
  4. 4.
    Fanger, M.W., Shen, L., Pugh, J. and Bernier, G.M., Proc. Natl. Acad. Sci. USA 77, 3640, 1980.PubMedCrossRefGoogle Scholar
  5. 5.
    Gauldie, J., Richards, C. and Lamontagne, L., Mol. Immunol. 20, 1029, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    Richards, C.D. and Gauldie, J., Am. Rev. Respir. Dis. 132, 82, 195.Google Scholar
  7. 7.
    Boltz-Nitulescu, G., Bazin, H. and Spiegelberg, H.L., J. Exp. Med. 154, 374, 1981.PubMedCrossRefGoogle Scholar
  8. 8.
    Reynolds, H.Y., Atkinson, J.P., Newball, H.H. and Frank, M.M., J. Immunol. 114, 1813, 1975.PubMedGoogle Scholar
  9. 9.
    Reynolds, H.Y., Kazmierowski, J.A., Newball, H.H., J. Clin. Invest. 56, 376, 1975.PubMedCrossRefGoogle Scholar
  10. 10.
    Johnson, K.J., Wilson, B.S., Till, G.O. and Ward, P.A., J. Clin. Invest. 74, 358, 1984.PubMedCrossRefGoogle Scholar
  11. 11.
    Acosta Altamirano, G., Barranco-Acosta, C., Van Roost, E. and Vaerman, J.-P., Mol. Immunol. 17, 1525, 1980.CrossRefGoogle Scholar
  12. 12.
    Rits, M., Cormont, F., Bazin, H., Meykens, R. and Vaerman, J.-P., J. Immunol. Meth. 89, 81, 1986.CrossRefGoogle Scholar
  13. 13.
    The, T.H., Conjugatie van fluoresceine isothiocyanaat aan antistoffen. Thesis, Aamstelstad Drukkerij, Amsterdam, 1967.Google Scholar
  14. 14.
    Sancho, J., Gonzalez, E. and Egido, J., Immunology 57, 37, 1986.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Y. Sibille
    • 1
  • B. Chatelain
    • 1
  • Ph. Staquet
    • 1
  • M. Rits
    • 1
  • J.-P. Vaerman
    • 1
  1. 1.Experimental Medicine Unit (ICP) and University Hospital of Mont-GodinneCatholic University of LouvainBelgium

Personalised recommendations